# PCBP1

Source: https://onco.cc/targets/pcbp1/  
OnCo record `pcbp1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PCBP1 (Poly(rC)-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.

## Summary

Single-stranded nucleic acid binding protein that binds preferentially to oligo dC. Together with PCBP2, required for erythropoiesis, possibly by regulating mRNA splicing.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.21, somatic mutation 0.77). IntOGen calls it a driver in 9 cohorts (5 activating, 4 loss-of-function), covering Burkitt Lymphoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Malignant Lymphoma, Papillary Renal Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: poly(rC) binding protein 1; Poly(rC)-binding protein 1; HNRPE1; hnRNP-E1; HNRPX; hnRNP-X
- Tags: cancer-genes-wave
- Symbol: PCBP1
- Class: oncogene
- Biology: Single-stranded nucleic acid binding protein that binds preferentially to oligo dC. Together with PCBP2, required for erythropoiesis, possibly by regulating mRNA splicing. Location: Nucleus; Cytoplasm (UniProt). Locus 2p13.3 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.58 with colorectal cancer (MONDO_0005575); IntOGen driver in 5 cohorts (COAD, COADREAD); Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM); Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC); Burkitt lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (BL); Papillary renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:8647: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8647
- UniProt Q15365: https://www.uniprot.org/uniprotkb/Q15365/entry
- NCBI Gene 5093: https://www.ncbi.nlm.nih.gov/gene/5093
- Ensembl ENSG00000169564: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169564

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Papillary renal cell carcinoma](https://onco.cc/cancers/papillary-rcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/pcbp1.json